Financial Performance - The company's operating revenue for Q1 2025 was ¥101,199,221.48, representing a decrease of 17.43% compared to ¥122,559,648.25 in the same period last year[4] - The net profit attributable to shareholders was -¥17,433,344.55, worsening from -¥11,850,583.19 year-over-year[4] - The net cash flow from operating activities was -¥94,058,756.82, slightly improved from -¥96,963,002.49 in the previous year[4] - Total revenue for Q1 2025 was CNY 101,199,221.48, a decrease of 17.4% compared to CNY 122,559,648.25 in Q1 2024[18] - Net loss for Q1 2025 was CNY 25,433,828.07, compared to a net loss of CNY 16,002,665.06 in Q1 2024, representing an increase in loss of 58.9%[19] - The total comprehensive income for the first quarter of 2025 was -25,433,828.07 RMB, compared to -16,002,665.06 RMB in the first quarter of 2024, indicating a decline[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,417,566,990.38, down 2.80% from ¥2,487,288,265.92 at the end of the previous year[5] - The company's total assets decreased to CNY 2,417,566,990.38 from CNY 2,487,288,265.92, a decline of 2.8%[17] - Total liabilities decreased to CNY 922,834,172.17 from CNY 967,121,619.64, a reduction of 4.6%[16] - The company's total equity decreased to CNY 1,494,732,818.21 from CNY 1,520,166,646.28, a decline of 1.7%[17] Cash Flow - The cash flow from operating activities showed a significant decline, impacting liquidity and operational flexibility[19] - Cash inflow from operating activities totaled 121,181,325.80 RMB in Q1 2025, down from 130,917,730.32 RMB in Q1 2024[21] - The net cash flow from investing activities was -10,332,107.19 RMB in Q1 2025, an improvement from -55,200,335.12 RMB in Q1 2024[22] - Total cash outflow from operating activities was 215,240,082.62 RMB in Q1 2025, compared to 227,880,732.81 RMB in Q1 2024[22] - The company received 77,476,300.00 RMB from financing activities in Q1 2025, down from 106,381,513.11 RMB in Q1 2024[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,860[9] - The top shareholder, Xia Jun, holds 24,750,839 shares, representing 17.99% of total shares[10] - The second-largest shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holds 16,812,069 shares, accounting for 12.22%[10] - The company has a total of 9,861,786 shares held by Hongyun Jiukang Data Technology (Beijing) Co., Ltd., which is 7.17% of total shares[10] - The total number of shares held by the top 10 shareholders includes significant stakes from various investment funds, indicating strong institutional interest[11] Research and Development - Research and development expenses totaled ¥47,758,469.77, a decrease of 20.10% from ¥59,773,809.35, accounting for 47.19% of operating revenue[5] - Research and development expenses for Q1 2025 were CNY 34,429,266.72, up 7.3% from CNY 32,077,752.04 in Q1 2024[18] Management and Strategy - The company has committed to ensuring the accuracy and completeness of its financial information, with management taking legal responsibility for the report[2] - The company has not disclosed any significant new strategies or product developments during the earnings call[13] - The company plans to focus on enhancing data resources and technology development to drive future growth[18] - The company is exploring market expansion opportunities and potential mergers and acquisitions to strengthen its market position[19] Earnings Per Share - The diluted earnings per share for the period was -¥0.13, compared to -¥0.09 in the same period last year[5] - The company reported a basic and diluted earnings per share of -0.13 RMB for Q1 2025, compared to -0.09 RMB in Q1 2024[20] Other Information - The company reported non-recurring gains and losses totaling ¥526,350.33 for the period[7] - The company did not report any net profit from the merged entity prior to the merger, with previous net profit also reported as 0 RMB[20] - The company has not adopted new accounting standards or interpretations for the year 2025[23] - There are no other important reminders regarding the company's operational situation during the reporting period[13]
嘉和美康(688246) - 2025 Q1 - 季度财报